Abstract

Routine use of platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) has shown the greatest benefits in patients with high risk for complications and in those with inadequate platelet antagonism. Now, in a partially industry-supported, multicenter, double-blind trial, researchers randomized 2159 low- and intermediate-risk patients (>95% in Europe) to placebo or the GPIIb/IIIa inhibitor abciximab. …

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.